Staurosporine

製品コードS1421 別名:CGP 41251

Staurosporine化学構造

分子量(MW):466.53

Staurosporineは1種の有効なPKC阻害剤で、無細胞試験でPKCα、PKCγ とPKCηに作用します。そして、これらのIC50値は2 nM、5 nM と 4 nMそれぞれに分かれます。StaurosporineはPKCδ(20 nM)とPKCε(73 nM)に作用することが弱くて、PKCζ (1086 nM)に対する活性も低いですが、他のキナーゼ(例えば、PKA、PKG、S6K、CaMKII等)に抑制活性を現れます。臨床3期。

サイズ 価格 在庫  
USD 340 あり

カスタマーフィードバック(3)

  • Intracellular concentration of HSF1-phosphoserine 326, total HSF1, S6 kinase-phosphothreonine-389, total S6 kinase and β-actin, without or with heat shock in HeLa cells pretreated with mTOR inhibitors rapamycin (30 nM) and KU0063794 (2 uM) and kinase inhibitor staurosporine (100 nM) for 2 hr. Relative levels of HSF1-phosphoserine 326 in cells after the various treatments were determined by densitometric analysis of X-ray films, normalized to untreated cells (lane 1), and are indicated below the representation of the immunoblots.

    PLoS One 2012 7(6), e39679. Staurosporine purchased from Selleck.

    J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

  • J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

製品安全説明書

PKC阻害剤の選択性比較

生物活性

製品説明 Staurosporineは1種の有効なPKC阻害剤で、無細胞試験でPKCα、PKCγ とPKCηに作用します。そして、これらのIC50値は2 nM、5 nM と 4 nMそれぞれに分かれます。StaurosporineはPKCδ(20 nM)とPKCε(73 nM)に作用することが弱くて、PKCζ (1086 nM)に対する活性も低いですが、他のキナーゼ(例えば、PKA、PKG、S6K、CaMKII等)に抑制活性を現れます。臨床3期。
靶点
PKCα [1]
(Cell-free assay)
c-Fgr [2] phosphorylase kinase [2] PKCη [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
2 nM 2 nM 3 nM 4 nM 5 nM
In vitro試験

Staurosporine, a microbial alkaloid, significantly inhibits protein kinase C from rat brain with IC50 of 2.7 nM. Staurosporine displays strong inhibitory effect against HeLa S3 cells with IC50 of 4 nM. [1] Staurosporine also inhibits a variety of other protein kinases, including PKA, PKG, phosphorylase kinase, S6 kinase, Myosin light chain kinase (MLCK), CAM PKII, cdc2, v-Src, Lyn, c-Fgr, and Syk with IC50 of 15 nM, 18 nM, 3 nM, 5 nM, 21 nM, 20 nM, 9 nM, 6 nM, 20 nM, 2 nM, and 16 nM, respectively. [2] Staurosporine (1 μM) induces >90% apoptosis in PC12 cells. Consistently, Staurosporine treatment induces a rapid and prolonged elevation of intracellular free calcium levels [Ca2+]i, accumulation of mitochondrial reactive oxygen species (ROS), and subsequent mitochondrial dysfunction. [3] The apoptosis of MCF7 cells induced by Staurosporine can be enhanced by the expression of functional caspase-3 via caspase-8 activation and Bid cleavage. [4] Staurosporine treatment at 1 μM only partially inhibits IL-3-stimulated Bcl2 phosphorylation but completely blocks PKC-mediated Bcl2 phosphorylation. [5] Staurosporine induces apoptosis of human foreskin fibroblasts AG-1518, depending on the lysosomal cathepsins D mediated cytochrome c release and caspase activation. [6] In addition to activating the classical mitochondrial apoptosis pathway, Staurosporine triggers a novel intrinsic apoptosis pathway, relying on the activation of caspase-9 in the absence of Apaf-1. [7]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human HeLa cells NU\qVFU2S3m2b4TvfIlkyqCjc4PhfS=> NULmOIVoPDhiaB?= M2mxc2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME20[U0xPiEQvF2u M1fuN|IyOzh6MUmx
human colon cancer cell line (LoVo cells) NX23ZXQ6WHKxbHnm[ZJifGmxbjDhd5NigQ>? NIn5OJJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIHPvcI9vKGOjbnPldkBk\WyuIHzpcoUhMEyxVn:gZ4VtdHNrIIXzbY5oKE2WVDDhd5NigSxiSVO1NF0xNjByMTFOwG0v M37FNlEyPTlzNUC1
human LoVo cells MV3Qdo9tcW[ncnH0bY9vKGG|c3H5 NEPwOG01QCC2bzC3NkBp MljBRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCOb2\vJINmdGy|IHHmeIVzKDR6IITvJFczKGi{czDifUBOXFRiYYPzZZk> MX[yNlE5Ojl{OR?=
P19 cells NGjzXoVHfW6ldHnvckBie3OjeR?= MV3Jcohq[mm2aX;uJI9nKFCuYYTlcIV1NWSncnn2[YQh\3Kxd4ToJIZi[3SxcjDy[YNmeHSxcjDpckBROTliY3XscJMtKEmFNUC9NE4xODJizszNMi=> NGHiSWkyPTd5MUSxPS=>
human BJ cells MVTDfZRwfG:6aXRCpIF{e2G7 NYWy[GlkPzJiaB?= NFfNXnVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBDUiClZXzsd{Bi\nSncjC3NkBpenNiYomgR4Ft[2WrbjDBUUBie3OjeTygTWM2OD1yLkCwNkDPxE1w MVeyNlkzOTB6MR?=
human HT-29 cells MYLGeY5kfGmxbjDhd5NigQ>? NF;FeGczKGh? NEXp[oNG\m[nY4Sgc44hdWm2b3Poc45lemmjbDDt[Y1jemGwZTDwc5RmdnSrYXygbY4hcHWvYX6gTHQuOjliY3XscJMh[W[2ZYKgNkBpenNidYPpcochUkNvMTDzeIFqdmmwZzDifUBndHWxcnXzZ4Vv[2ViYYPzZZk> MVKyNVQzQDN5NR?=
human A549 cells NVnjU3o1S3m2b4TvfIlkyqCjc4PhfS=> M3PNb|czKGh? MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIH3leIhw\A>? MUCxPFQ5PDd5NR?=
human HT-29 cells M{DNTGZ2dmO2aX;uJIF{e2G7 M2[0NmlvcGmkaYTpc44hd2ZibXn0c4Npd26mcnnhcEBu\W2kcnHu[UBxd3SnboTpZYwhcW5iaIXtZY4hUFRvMkmgZ4VtdHNidYPpcochUkNzIHT5[UB{fGGrbnnu[{BjgSCobIXvdoV{[2WwY3WgdIxifGVicnXh[IVzKGG|c3H5MEBKSzVyPUKuOUBvVQ>? M2W5flIyPTF|Mkmz
human HT-29 cells NX;Jb|hyTnWwY4Tpc44h[XO|YYm= M13YPFIhcA>? MmXLTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCKVD2yPUBk\WyuczDhd5Nme3OnZDDy[YR2[3Srb36gc4YhdWm2b3Poc45lemmjbDDt[Y1jemGwZTDwc5RmdnSrYXygZYZ1\XJiMjDodpMh[nlidYPpcochUkNzIIP0ZYlvcW6pIHL5JIZtfW:{ZYPj[Y5k\SClZXzsMYJie2WmIHHzd4F6NCCHQ{WwQVIvPiCwTT6= NV23d5pzOjF7N{OxNFE>
Sf9 cells NFzKOoJHfW6ldHnvckBie3OjeR?= M{HSb2lvcGmkaYTpc44hd2ZiaIXtZY4hW3mtIHX4dJJme3OnZDDpckBU\jliY3XscJMtKEmFNUC9N{BvVS5? M1jrTFE5QDJ|N{i0
human HUVEC MXzQdo9tcW[ncnH0bY9vKGG|c3H5 M2ToOFQ5KHSxIEeyJIg> NUTZdpl3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWXZGSyCjZoTldkA1QCC2bzC3NkBpenNiYomgUXRVKGG|c3H5 Mlu1NlIyQDJ7Mkm=
P19 cells MWrGeY5kfGmxbjDhd5NigQ>? NUXGOJBsUW6qaXLpeIlwdiCxZjDQdo91\WmwIFvpcoF{\SCDIHnuJHAyQSClZXzsd{whUUN3ME20JI5ONg>? NEHoUIwyPTd5MUSxPS=>
Sf9 cells NUK4SHhxTnWwY4Tpc44h[XO|YYm= NVizbYRwUW6qaXLpeIlwdiCxZjDoeY1idiCIeX6g[ZhxemW|c3XkJIlvKFOoOTDj[YxteyCjZoTldkAyKG2rbjDifUBGVEmVQTDpckBxemW|ZX7j[UBw\iBzIIXtc4wwVCCDVGC= NVKwWHR{OTd|MUW4OVM>
Sf21 cells NGDab45HfW6ldHnvckBie3OjeR?= NGj6SJRKdmirYnn0bY9vKG:oIFrBT|Mh\XiycnXzd4VlKGmwIGPmNlEh[2WubIOsJGlEPTB;NjDuUU4> MY[xO|A5QDB3OR?=
human colon carcinoma cell line HCT116 M4\R[GZ2dmO2aX;uJIF{e2G7 M3fKc2NwdmOnboTyZZRqd25icnXxeYlz\WRiZn;yJIdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJINwdG:wIHPhdoNqdm:vYTDj[YxtKGyrbnWgTGNVOTF4LDDJR|UxRTZibl2u MofZNVU2Ozd|NEW=
human ST486 cells NFzBOpFRem:uaX\ldoF1cW:wIHHzd4F6 NVX4dIRCPDhidH:gO|IhcA>? M4HFcWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU2S0PFYh[2WubIOgZYZ1\XJiNEigeI8hPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF04KG6PLh?= MmHrNlIyQDJ7Mkm=
human MDA-MB-231 cells MXXDfZRwfG:6aXRCpIF{e2G7 M3X5WlczKGh? Mn\lR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDh[pRmeiB5MjDodpMh[nlic4Xs[o9zcG:mYX3pcoUhSiCvZYToc4QtKEeLNUC9O{4yKG6PLh?= MXKxPFQ5PDd5NR?=
P19 cells M2TLbWZ2dmO2aX;uJIF{e2G7 Ml\hTY5pcWKrdHnvckBw\iCFeXPsbY4u\GWyZX7k[Y51KGurbnHz[UAyKGmwIGCxPUBk\WyuczygTWM2OD16IH7NMi=> MYWxOVc4OTRzOR?=
human DLD1 cells Mn7EVJJwdGmoZYLheIlwdiCjc4PhfS=> MWC0PE04OiCq MnHsRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCGTFSxJINmdGy|IHHmeIVzKDR6IITvJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9PUBvVS5? NGqzVHAzOjF6MkmyPS=>
insect cells M1faW2Z2dmO2aX;uJIF{e2G7 NXHDcYFzUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDQbY0yKGW6cILld5Nm\CCrbjDpcpNm[3RiY3XscJMh[nliSGTSSkwhUUN3ME2xNEBvVS5? Mn\JNVkyPzlyN{[=
V79 MZ cells MUTGeY5kfGmxbjDhd5NigQ>? M4n3ZmlvcGmkaYTpc44hd2ZiaIXtZY4h[Wymb4P0[ZJwdmVic4nueIhie2ViZYjwdoV{e2WmIHnuJHY4QSCPWjDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGGuZH;zeIVzd26nIIP5cpRp\XOrczygTWM2OD1zMTDuUU4> MUKyOFQzOjVzOR?=
P19 cells MV\GeY5kfGmxbjDhd5NigQ>? M2O3fmlvcGmkaYTpc44hd2ZiVnHzZ5Vt[XJiZX7kc5Rp\WyrYXyg[5Jwf3SqIH\hZ5RweiC{ZXPldJRweiCrbjDQNVkh[2WubIOsJGlEPTB;MUSgcm0v NHHpbpkyPTd5MUSxPS=>
Sf9 cells NH3FfY1HfW6ldHnvckBie3OjeR?= MX2yNEBucW6| NYW2eWhZUW6qaXLpeIlwdiCxZjDoeY1idiCIeX6g[ZhxemW|c3XkJIlvKFOoOTDj[YxteyCjZoTldkAzOCCvaX7zJIJ6KEWOSWPBJIlvKHC{ZYPlcoNmKG:oIEGgeY1wdC:OIFHUVEwhUUN3ME2xOUBvVS5? NHjJUGwyPzNzNUi1Ny=>
human PBMC NE\rfphHfW6ldHnvckBie3OjeR?= M1TCbVI1KGh? M1e2e3N2eHC{ZYPzbY9vKG:oIFnMNkBxem:mdXP0bY9vKGmwIHj1cYFvKFCETVOgZYZ1\XJiMkSgbJJ{KGK7IFXMTXNCNCCLQ{WwQVE3KG6PLh?= NUPiV5VEOTh3OEWwOFY>
human A549 cells M4fDc2N6fG:2b4jpZ:Kh[XO|YYm= MojjOFghcA>? MonER5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5JEwhUUN3ME2yNEBvVS5? M1jKVlI2QDJ3OUO0
human CEM cells NHe0T4NEgXSxdH;4bYPDqGG|c3H5 M2PhcFczKGh? M4LlfGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNGVSClZXzsd{Bi\nSncjC3NkBpenNiYomgR4Ft[2WrbjDBUUBie3OjeTygTWM2OD1{MzDuUU4> NXHtcIxROjJ7MkGwPFE>
human HeLa cells MnrSR5l1d3SxeHnjxsBie3OjeR?= Mnv4OFghcA>? NXrPXpR1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVI2KG6PLh?= Mk\kNlU5OjV7M{S=
human PC3 cells MnvzR5l1d3SxeHnjxsBie3OjeR?= MVG0PEBp NIP4ZY1EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUAtKEmFNUC9N|Ehdk1w M1j6eFI2QDJ3OUO0
human SF268 cells NY\hNpZ2S3m2b4TvfIlkyqCjc4PhfS=> MUe0PEBp NX;ZS2IxS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0Z{NkigZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF01PCCwTT6= MWiyNVUyOzJ7NB?=
human MCF7 cells NVT1cZNES3m2b4TvfIlkyqCjc4PhfS=> MmTCOFghcA>? NVTBemRmS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVUxKG6PLh?= M3;EWFIyOzh6MUmx
HEK293 cells M2r2UmN6fG:2b4jpZ:Kh[XO|YYm= MmrIO|IhcA>? NYPtXGtFS3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYLHcI8h[XO|YYmsJGlEPTB;NU[gcm0v MWGyOFc3OzJ4Mh?=
HUE cells NWXxPXR[TnWwY4Tpc44h[XO|YYm= MljPPVAhdWmwcx?= MWjJcohq[mm2aX;uJI9nKF[HR1\SNkBqdiCKVVWgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCYRVfGMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB1emWjdHXkJIZweiB7MDDtbY5{KGKnZn;y[UBXTUeIIHPoZYxt\W6pZTDifUBGVEmVQTygTWM2OD15MDDuUU4> MYmyNFE4ODF4Mx?=
human A431 cells MW\DfZRwfG:6aXRCpIF{e2G7 M1W3Z|I1KCCq MXrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOFMyKGOnbHzzJIFnfGW{IEK0JIhzeyC3c3nu[{BCdm6neHnuJHZmTkmWQz;wdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pIHL5JG1VXCCjc4PhfUwhUUN3ME23NEBvVS5? M3vZUlIzPTRzMEWx
human Jurkat cells NU\ocXFqWHKxbHnm[ZJifGmxbjDhd5NigQ>? MXPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFrBT|Mh\XiycnXzd4lv\yCLTEKtd5RqdXWuYYTl[EBpfW2jbjDKeZJs[XRiY3XscJMtKEmFNUC9O|Ehdk1w M4fsVFE6PDJ5MkCz
HEK293 cells NHXYR4hHfW6ldHnvckBie3OjeR?= M1Ttb2lvcGmkaYTpc44hd2ZiSVytPEBz\WynYYPlJIJ6KEiHS{K5N{Bk\WyuczDlfJBz\XO|aX7nJHBMSy2kZYThNkwhUUN3ME23O{BvVS5? MVKxOVc4OTRzOR?=
human KE-97 cells M{jsUmN6fG:2b4jpZ:Kh[XO|YYm= MWS3NkBp M1T2OmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtGNTl5IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0doUuT2yxIHz1cYlv\XOlZX70JINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTNizszNMi=> NXe0OlZbOjR|MkiyPFM>
human CHOK1 cells Mli1R5l1d3SxeHnjxsBie3OjeR?= M{LENVQ5KGh? MoXqR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2hQUzFiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4Phfg+9lCCLQ{WwQVAvOTNizszNMi=> NV3Yc41ROjF3MUOyPVQ>
mouse NIH/3T3 cells NFqx[5lEgXSxdH;4bYPDqGG|c3H5 M3mxOFk3KGh? MVTDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDOTWgwO1R|IHPlcIx{KGGodHXyJFk3KGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE4zKM7:TT6= NEDTboYzPDN4MUWyNS=>
human A2780 cells MUXDfZRwfG:6aXRCpIF{e2G7 MVS5OkBp NULhZll[S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTJ5OECgZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KFOUQjDhd5NigSxiSVO1NF0xNjJizszNMi=> MXyyOFM3OTV{MR?=
human 8505C cells MWTDfZRwfG:6aXRCpIF{e2G7 NVGxWmo3QTZiaB?= Moe5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gPFUxPUNiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlIh|ryPLh?= NHTrRXQzPDN4MUWyNS=>
human 518A2 cells MXLDfZRwfG:6aXRCpIF{e2G7 MnLOPVYhcA>? MX;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjC1NVhCOiClZXzsd{Bi\nSncjC5OkBpenNiYomgV3JDKGG|c3H589yNKEmFNUC9NE4zKM7:TT6= NYXOXnQzOjR|NkG1NlE>
human HuH7 cells NEfWVXVEgXSxdH;4bYPDqGG|c3H5 MUC3NkBp NUezVmJrS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUHWKNzDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeJJmNUeubzDseY1qdmW|Y3XueEBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ|IN88UU4> MV6yOFMzQDJ6Mx?=
FL5.12-Akt1 cells MXXQdo9tcW[ncnH0bY9vKGG|c3H5 M{OzTGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgSmw2NjF{LVHreFEh[2WubIOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvOjlizszNMi=> NX\qS5RUOTZ2MEO2NlY>
human MiaPaCa-2 cells MYjQdo9tcW[ncnH0bY9vKGG|c3H5 NFLsS4tCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3pZXBiS2FvMjDj[YxteyxiSVO1NF0xNjN5IN88UU4> M4X3PFE3PDF|N{iw
human BGC823 cells M3HTfWN6fG:2b4jpZ:Kh[XO|YYm= NEj0eYg4OiCq NH3YVG1EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBDT0N6MkOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRz\S2JbH:gcJVucW6nc3PlcpQh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|ODFOwG0v Mn3UNlQ{Ojh{OEO=
human MCF7 cells MUPDfZRwfG:6aXRCpIF{e2G7 Mm\wPVYhcA>? M1TnPWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlQh|ryPLh?= NVvFU29tOjR|NkG1NlE>
human A549 cells M4\hNmN6fG:2b4jpZ:Kh[XO|YYm= MYq5OkBp NGr2b5JEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGGodHXyJFk3KGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE43KM7:TT6= MXmyOFM3OTV{MR?=
HEK293 cells M2jnUmN6fG:2b4jpZ:Kh[XO|YYm= NYSyWJdvS3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzMEBGSzVyPUKg{txONg>? NUm0fZZ5OjV|MU[zNVc>
human Raji cells  NUPNSlZoS3m2b4TvfIlkyqCjc4PhfS=> M{OzRWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHJicmliY3XscJMtKEWFNUC9NkDPxE1w MofiNlU{OTZ|MUe=
human HepG2 cells M4fScGN6fG:2b4jpZ:Kh[XO|YYm= NULXbpZPS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNuIFXDOVA:OiEQvF2u M3XiZlI2OzF4M{G3
human BJ cells M2XQTGN6fG:2b4jpZ:Kh[XO|YYm= MWTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDCTkBk\WyuczygSWM2OD1{IN88UU4> NHLVUm4zPTNzNkOxOy=>
human U937 cells M4XjSWN6fG:2b4jpZ:Kh[XO|YYm= MmjTR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWVk{PyClZXzsd{whUUN3ME2yJO69VS5? MmK4NVcxQDhyNke=

... Click to View More Cell Line Experimental Data

In vivo試験 In the gerbil and rat ischemia models, Staurosporine pretreatment (0.1-10 ng) before ischemia prevents neuronal damage in a dose-dependent manner, suggesting the involvement of PKC in CAl pyramidal cell death after ischemia. [8]

プロトコル(参考用のみ)

キナーゼアッセイ:

[1]

+ 展開

Enzyme assay and binding assay:

Protein kinase C is assayed in a reaction mixture (0.25 mL) containing 5 μmol of Tris/HCl, pH 7.5, 2.5 μmol of magnesium acetate, 50 μg of histone II S, 20 μg of phosphatidylserine, 0.88 μg of diolein, 125 nmol of CaCl2, 1.25 nmol of [γ-32]ATP (5-10 × 104 cpm/nmol) and 5 μg of partially purified enzyme. The binding of [3H]PDBu to protein kinase C is determined: Reaction mixture (200 μL contained 4 μmo1 of Tris/malate, pH 6.8, 20 μmol of KCl, 30 nmol of CaC12, 20 μg of phosphatidylserine, 5 μg of partially purified protein kinase C, 0.5% (final concentration) of DMSO,10 pmol of [3H]PDBu (l-3 × 104 cpm/pmol) and 10 μL of various amounts of Staurosporine.
細胞アッセイ:

[3]

+ 展開
  • 細胞株: PC12
  • 濃度: Dissolved in DMSO, final concentration 1 μM
  • 反応時間: ~32 hours
  • 実験の流れ:

    Cells are exposed to Staurosporine for ~32 hours. Cells are fixed in 4% paraformaldehyde and stained with the DNA-binding dye Hoechst 33342. Cells are visualized under epifluorescence illumination, and the percentage of apoptotic cells (cells with condensed and fragmented DNA) is determined.


    (参考用のみ)
動物実験:

[8]

+ 展開
  • 動物モデル: Male Mongolian gerbils or male Wistar rats subjected to transient ischemia
  • 製剤: Dissolved in DMSO, and diluted in saline
  • 投薬量: ~10 ng
  • 投与方法: Stereotaxically administered into the bilateral CAl subfield of the hippocampus
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 4 mg/mL (8.57 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
体内

* <1 mg/mlは製品が微弱に溶解する或いは溶解しないことを示します。
* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 466.53
化学式

C28H26N4O3

CAS No. 62996-74-1
保管
in solvent
別名 CGP 41251

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00301938 Completed Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasms|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) December 2005 Phase 1
NCT00098956 Completed Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer National Cancer Institute (NCI) January 2005 Phase 2
NCT00082017 Completed Lymphoma, Large-Cell, Ki-1|Lymphoma, T-Cell National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 2004 Phase 2
NCT00072267 Completed Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer University Health Network, Toronto|National Cancer Institute (NCI) January 2004 Phase 2
NCT00072189 Terminated Recurrent Melanoma|Stage IV Melanoma National Cancer Institute (NCI) November 2003 Phase 2
NCT00030888 Unknown status Kidney Cancer University of California, San Francisco|National Cancer Institute (NCI) December 2002 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

PKC信号経路図

相関PKC製品

Tags: Staurosporineを買う | Staurosporine ic50 | Staurosporine供給者 | Staurosporineを購入する | Staurosporine費用 | Staurosporine生産者 | オーダーStaurosporine | Staurosporine化学構造 | Staurosporine分子量 | Staurosporine代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID